Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis

Kenichi Watanabe, Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Rajarajan A. Thandavarayan, Narasimman Gurusamy, Meilei Ma, Wawaimuli Arozal, Flori R. Sari, Arun Lakshmanan, Somasundaram Arumugam, Vivian Soetikno, Varatharajan Rajavel, Kenji Suzuki

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Autoimmune responses and inflammation are involved in the pathogenesis of many cardiovascular diseases. There is compelling evidence that inflammatory mechanisms may contribute to progressive heart failure. Thus, myocardial infiltration of lymphocytes and mononuclear cells, increased expression of pro-inflammatory chemokines and cytokines and circulating autoantibodies are frequently observed in myocarditis and dilated cardiomyopathy (DCM). Experimental autoimmune myocarditis (EAM) in rodents may be elicited by immunization of cardiac myosin and EAM in rats mimics human fulminant myocarditis in the acute phase and human DCM in the chronic phase. Our animal model, EAM was demonstrated to progress into the clinicopathological state similar to DCM in the chronic phase, and was found to be characterized by the enlargement of the heart, dilatation of ventricles, diffuse and extensive myocardial fibrosis, besides being a cellular immunity and inflammation mediated disease. Severity of myocarditis was characterized by increased inflammation, cardiac fibrosis and decreased myocardial performance in rats with DCM. Pharmacological interventions such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) significantly attenuated the myosin-induced inflammation and cardiac fibrosis and thereby improving myocardial function in rats with DCM. A growing body of evidence shows that ACEI and ARBs contribute to the pharmaceutical management of patients with heart failure mediated by immune and inflammatory response. The purpose of this review is to emphasize the role of inflammation and myocardial fibrosis in rats with DCM after EAM and study the effects of pharmacological interventions such as ACEI, ARBs in the treatment of heart failure through the suppression of inflammatory cytokines and fibrosis.

Original languageEnglish
Pages (from-to)218-225
Number of pages8
JournalInflammation and Allergy - Drug Targets
Volume10
Issue number3
DOIs
Publication statusPublished - 1 Jan 2011
Externally publishedYes

Fingerprint

Myocarditis
Dilated Cardiomyopathy
Fibrosis
Inflammation
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Pharmacology
Cardiac Myosins
Cytokines
Myosins
Treatment Failure
Autoimmunity
Chemokines
Cellular Immunity
Autoantibodies
Heart Ventricles
Dilatation
Rodentia
Immunization

Keywords

  • Angiotensin converting enzyme inhibitors
  • Angiotensin receptor blockers
  • Dilated cardiomyopathy
  • Experimental autoimmune myocarditis
  • Inflammation
  • Myocardial fibrosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Watanabe, K., Sukumaran, V., Veeraveedu, P. T., Thandavarayan, R. A., Gurusamy, N., Ma, M., ... Suzuki, K. (2011). Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis. Inflammation and Allergy - Drug Targets, 10(3), 218-225. https://doi.org/10.2174/187152811795564091

Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis. / Watanabe, Kenichi; Sukumaran, Vijayakumar; Veeraveedu, Punniyakoti T.; Thandavarayan, Rajarajan A.; Gurusamy, Narasimman; Ma, Meilei; Arozal, Wawaimuli; Sari, Flori R.; Lakshmanan, Arun; Arumugam, Somasundaram; Soetikno, Vivian; Rajavel, Varatharajan; Suzuki, Kenji.

In: Inflammation and Allergy - Drug Targets, Vol. 10, No. 3, 01.01.2011, p. 218-225.

Research output: Contribution to journalReview article

Watanabe, K, Sukumaran, V, Veeraveedu, PT, Thandavarayan, RA, Gurusamy, N, Ma, M, Arozal, W, Sari, FR, Lakshmanan, A, Arumugam, S, Soetikno, V, Rajavel, V & Suzuki, K 2011, 'Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis', Inflammation and Allergy - Drug Targets, vol. 10, no. 3, pp. 218-225. https://doi.org/10.2174/187152811795564091
Watanabe, Kenichi ; Sukumaran, Vijayakumar ; Veeraveedu, Punniyakoti T. ; Thandavarayan, Rajarajan A. ; Gurusamy, Narasimman ; Ma, Meilei ; Arozal, Wawaimuli ; Sari, Flori R. ; Lakshmanan, Arun ; Arumugam, Somasundaram ; Soetikno, Vivian ; Rajavel, Varatharajan ; Suzuki, Kenji. / Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis. In: Inflammation and Allergy - Drug Targets. 2011 ; Vol. 10, No. 3. pp. 218-225.
@article{b632a27bd18b4c59820a7a04aa5ebf46,
title = "Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis",
abstract = "Autoimmune responses and inflammation are involved in the pathogenesis of many cardiovascular diseases. There is compelling evidence that inflammatory mechanisms may contribute to progressive heart failure. Thus, myocardial infiltration of lymphocytes and mononuclear cells, increased expression of pro-inflammatory chemokines and cytokines and circulating autoantibodies are frequently observed in myocarditis and dilated cardiomyopathy (DCM). Experimental autoimmune myocarditis (EAM) in rodents may be elicited by immunization of cardiac myosin and EAM in rats mimics human fulminant myocarditis in the acute phase and human DCM in the chronic phase. Our animal model, EAM was demonstrated to progress into the clinicopathological state similar to DCM in the chronic phase, and was found to be characterized by the enlargement of the heart, dilatation of ventricles, diffuse and extensive myocardial fibrosis, besides being a cellular immunity and inflammation mediated disease. Severity of myocarditis was characterized by increased inflammation, cardiac fibrosis and decreased myocardial performance in rats with DCM. Pharmacological interventions such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) significantly attenuated the myosin-induced inflammation and cardiac fibrosis and thereby improving myocardial function in rats with DCM. A growing body of evidence shows that ACEI and ARBs contribute to the pharmaceutical management of patients with heart failure mediated by immune and inflammatory response. The purpose of this review is to emphasize the role of inflammation and myocardial fibrosis in rats with DCM after EAM and study the effects of pharmacological interventions such as ACEI, ARBs in the treatment of heart failure through the suppression of inflammatory cytokines and fibrosis.",
keywords = "Angiotensin converting enzyme inhibitors, Angiotensin receptor blockers, Dilated cardiomyopathy, Experimental autoimmune myocarditis, Inflammation, Myocardial fibrosis",
author = "Kenichi Watanabe and Vijayakumar Sukumaran and Veeraveedu, {Punniyakoti T.} and Thandavarayan, {Rajarajan A.} and Narasimman Gurusamy and Meilei Ma and Wawaimuli Arozal and Sari, {Flori R.} and Arun Lakshmanan and Somasundaram Arumugam and Vivian Soetikno and Varatharajan Rajavel and Kenji Suzuki",
year = "2011",
month = "1",
day = "1",
doi = "10.2174/187152811795564091",
language = "English",
volume = "10",
pages = "218--225",
journal = "Current Drug Targets: Inflammation and Allergy",
issn = "1871-5281",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis

AU - Watanabe, Kenichi

AU - Sukumaran, Vijayakumar

AU - Veeraveedu, Punniyakoti T.

AU - Thandavarayan, Rajarajan A.

AU - Gurusamy, Narasimman

AU - Ma, Meilei

AU - Arozal, Wawaimuli

AU - Sari, Flori R.

AU - Lakshmanan, Arun

AU - Arumugam, Somasundaram

AU - Soetikno, Vivian

AU - Rajavel, Varatharajan

AU - Suzuki, Kenji

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Autoimmune responses and inflammation are involved in the pathogenesis of many cardiovascular diseases. There is compelling evidence that inflammatory mechanisms may contribute to progressive heart failure. Thus, myocardial infiltration of lymphocytes and mononuclear cells, increased expression of pro-inflammatory chemokines and cytokines and circulating autoantibodies are frequently observed in myocarditis and dilated cardiomyopathy (DCM). Experimental autoimmune myocarditis (EAM) in rodents may be elicited by immunization of cardiac myosin and EAM in rats mimics human fulminant myocarditis in the acute phase and human DCM in the chronic phase. Our animal model, EAM was demonstrated to progress into the clinicopathological state similar to DCM in the chronic phase, and was found to be characterized by the enlargement of the heart, dilatation of ventricles, diffuse and extensive myocardial fibrosis, besides being a cellular immunity and inflammation mediated disease. Severity of myocarditis was characterized by increased inflammation, cardiac fibrosis and decreased myocardial performance in rats with DCM. Pharmacological interventions such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) significantly attenuated the myosin-induced inflammation and cardiac fibrosis and thereby improving myocardial function in rats with DCM. A growing body of evidence shows that ACEI and ARBs contribute to the pharmaceutical management of patients with heart failure mediated by immune and inflammatory response. The purpose of this review is to emphasize the role of inflammation and myocardial fibrosis in rats with DCM after EAM and study the effects of pharmacological interventions such as ACEI, ARBs in the treatment of heart failure through the suppression of inflammatory cytokines and fibrosis.

AB - Autoimmune responses and inflammation are involved in the pathogenesis of many cardiovascular diseases. There is compelling evidence that inflammatory mechanisms may contribute to progressive heart failure. Thus, myocardial infiltration of lymphocytes and mononuclear cells, increased expression of pro-inflammatory chemokines and cytokines and circulating autoantibodies are frequently observed in myocarditis and dilated cardiomyopathy (DCM). Experimental autoimmune myocarditis (EAM) in rodents may be elicited by immunization of cardiac myosin and EAM in rats mimics human fulminant myocarditis in the acute phase and human DCM in the chronic phase. Our animal model, EAM was demonstrated to progress into the clinicopathological state similar to DCM in the chronic phase, and was found to be characterized by the enlargement of the heart, dilatation of ventricles, diffuse and extensive myocardial fibrosis, besides being a cellular immunity and inflammation mediated disease. Severity of myocarditis was characterized by increased inflammation, cardiac fibrosis and decreased myocardial performance in rats with DCM. Pharmacological interventions such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) significantly attenuated the myosin-induced inflammation and cardiac fibrosis and thereby improving myocardial function in rats with DCM. A growing body of evidence shows that ACEI and ARBs contribute to the pharmaceutical management of patients with heart failure mediated by immune and inflammatory response. The purpose of this review is to emphasize the role of inflammation and myocardial fibrosis in rats with DCM after EAM and study the effects of pharmacological interventions such as ACEI, ARBs in the treatment of heart failure through the suppression of inflammatory cytokines and fibrosis.

KW - Angiotensin converting enzyme inhibitors

KW - Angiotensin receptor blockers

KW - Dilated cardiomyopathy

KW - Experimental autoimmune myocarditis

KW - Inflammation

KW - Myocardial fibrosis

UR - http://www.scopus.com/inward/record.url?scp=79958185781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958185781&partnerID=8YFLogxK

U2 - 10.2174/187152811795564091

DO - 10.2174/187152811795564091

M3 - Review article

VL - 10

SP - 218

EP - 225

JO - Current Drug Targets: Inflammation and Allergy

JF - Current Drug Targets: Inflammation and Allergy

SN - 1871-5281

IS - 3

ER -